sprifermin Report issue

Biologics Recombinant protein Experimental
AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW
  • Now
Sprifermin (INN), also known as recombinant human fibroblast growth factor 18 (rhFGF18), is a recombinant form of human fibroblast growth factor 18 (FGF18) which is under development by Merck and Nordic Bioscience for the treatment of osteoarthritis. As a recombinant form of FGF18, sprifermin is a potent agonist of the FGFR2 and FGFR3.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

as902330 | fgf-18 | fgf-18 protein, human | fgf18 protein, human | fgf-18 protein, mouse | fgf18 protein, mouse | fgf-18 protein, rat | fgf18 protein, rat | fibroblast growth factor 18 | fibroblast growth factor 18, human | fibroblast growth factor 18, mouse | fibroblast growth factor 18, rat | sprifermin

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Cartilage Diseases (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue